Clinical Trial Applications: Filter, Search, and view applications
# | Protocol No | Study Title | Investigator(s) & Site(s) | |
---|---|---|---|---|
336. |
ECCT/15/06/04 | A5316 A5316 Evaluating Pharmacokinetic Interactions with Vaginal Ring Contraceptives and Antiretroviral Therapy |
Principal Investigator(s) 1. Dr. Esther Mumbi Makanga Makanga 2. Dr. Victor Akelo Akelo 3. Dr.Victor O. Mudhune Mudhune 4. Dr. Kevin P. Cain Cain Site(s) in Kenya KEMRI- CDC |
View |
337. |
ECCT/18/11/01 | PrIMA PrEP Implementation for Mothers in Antenatal Care |
Principal Investigator(s) 1. Grace John-Stewart John-Stewart 2. Jared Baeten Site(s) in Kenya 1. Homa Bay County - 10 sites (Homa Bay county) 2. Siaya County - 10 sites (Siaya county) |
View |
338. |
ECCT/22/03/08 | CVIA 092 “ A Phase 3 Multicenter, Observer Blind, Randomized, Controlled Study to Evaluate Safety (Ages 6 Months to 45 Years) and Non-inferiority (Ages 9-12 Months) of Multi-dose and Single-dose Vial Formulations of EuTCV (Vi-CRM197 Typhoid Conjugate Vaccine) against Typbar TCV® and Lot-to-Lot Consistency of the Immune Response (Ages 9-12 Months) to Multi-dose Vial Formulation EuTCV in Healthy African Participants”. |
Principal Investigator(s) 1. Dr Lucy Koech Chepkurui Koech Site(s) in Kenya KEMRI/ KERICHO CRC |
View |
339. |
ECCT/15/01/02 | Study title An observational pilot study to characterize the immune response induced by the commercial Varicella Zoster Virus vaccine Zostavax® (Merck) in healthy adult females in Nairobi, Kenya. Clinical Phase IV |
Principal Investigator(s) 1. Prof Walter Jaoko Jaoko Site(s) in Kenya KAVI-INSTITUTE OF CLINICAL RESEARCH (KAVI-ICR) |
View |
340. |
ECCT/22/02/02 | The Women TAF-FTC Benchmark Safety and Pharmacokinetics of TAF-FTC Pre-exposure Prophylaxis in Kenyan Cisgender women |
Principal Investigator(s) 1. Dr. Nelly Rwamba Mugo Site(s) in Kenya KEMRI-CCR PHRD Thika |
View |